Overview
- Q3 revenue rose 23% to $2.51 billion and adjusted EPS hit $2.40, topping estimates as procedure volumes drove results.
- Worldwide procedures grew about 20% year over year, including ~19% for da Vinci and ~52% for Ion, with 427 da Vinci placements and 240 of them the new da Vinci 5.
- Management lifted 2025 da Vinci procedure growth guidance to approximately 17%–17.5% and projected gross margin of 67%–67.5%.
- FDA cleared AI-driven navigation software for the Ion bronchoscopy system, with a limited U.S. rollout in 2025 and a broader launch planned for 2026.
- Shares jumped roughly 16%–17% as multiple analysts raised targets; the company also repurchased 4 million shares, with international capex variability and margins noted as watch points.